MX2019011558A - Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido). - Google Patents

Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido).

Info

Publication number
MX2019011558A
MX2019011558A MX2019011558A MX2019011558A MX2019011558A MX 2019011558 A MX2019011558 A MX 2019011558A MX 2019011558 A MX2019011558 A MX 2019011558A MX 2019011558 A MX2019011558 A MX 2019011558A MX 2019011558 A MX2019011558 A MX 2019011558A
Authority
MX
Mexico
Prior art keywords
ido
hydroxycarbamimidoyl
indoleamine
dioxygenase
inhibitors
Prior art date
Application number
MX2019011558A
Other languages
English (en)
Inventor
Li Guoqing
Zhang Hongjun
Liu Kun
Pu Qinglin
Guo Liangqin
He Shuwen
Kozlowski Joseph
Nargund Ravi
Yu Wensheng
Li Derun
Achab Abdelghani
Han Yongxin
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2019011558A publication Critical patent/MX2019011558A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Se describe en el presente documento un compuesto de fórmula (I), o una sal farmacéuticamente aceptable del mismo: (ver Fórmula). También se describen en el presente documento los usos de los compuestos descritos en el presente en el tratamiento o prevención potencial de una enfermedad o trastorno asociado con IDO. También se describen en el presente documento composiciones que comprenden un compuesto descrito en el presente documento. Además, se describen en el presente documento usos de las composiciones en el tratamiento o prevención potencial de una enfermedad o trastorno asociado con IDO.
MX2019011558A 2017-03-29 2018-03-23 Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido). MX2019011558A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762478262P 2017-03-29 2017-03-29
PCT/US2018/023912 WO2018183097A1 (en) 2017-03-29 2018-03-23 Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors

Publications (1)

Publication Number Publication Date
MX2019011558A true MX2019011558A (es) 2019-11-28

Family

ID=63676744

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019011558A MX2019011558A (es) 2017-03-29 2018-03-23 Nuevos compuestos sustituidos de n'-hidroxicarbamimidoil-1,2,5-oxa diazol como inhibidores de indolamina 2,3-dioxigenasa (ido).

Country Status (11)

Country Link
US (1) US11034661B2 (es)
EP (1) EP3600299B1 (es)
JP (1) JP2020515528A (es)
KR (1) KR20190133171A (es)
CN (1) CN110461326A (es)
AU (1) AU2018243640A1 (es)
BR (1) BR112019020080A2 (es)
CA (1) CA3057312A1 (es)
MX (1) MX2019011558A (es)
RU (1) RU2765371C2 (es)
WO (1) WO2018183097A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019027856A1 (en) * 2017-08-02 2019-02-07 Merck Sharp & Dohme Corp. NOVEL SUBSTITUTED PYRIDINE COMPOUNDS AS INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASE (IDO)
EP3661909B1 (en) * 2017-08-02 2023-08-16 Merck Sharp & Dohme LLC Novel substituted phenyl compounds as indoleamine 2,3-dioxygenase (ido) inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006521377A (ja) * 2003-03-27 2006-09-21 ランケナー インスティテュート フォー メディカル リサーチ 新型ｉｄｏ阻害剤とその使用方法
CN101212967A (zh) * 2005-05-10 2008-07-02 因塞特公司 吲哚胺2,3-双加氧酶调节剂及其用法
CA2634198C (en) * 2005-12-20 2014-06-03 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
CL2007002650A1 (es) * 2006-09-19 2008-02-08 Incyte Corp Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras.
CA2663057C (en) * 2006-09-19 2015-12-08 Incyte Corporation N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase
AU2009268739B2 (en) * 2008-07-08 2014-05-08 Incyte Holdings Corporation 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
US10988487B2 (en) 2016-08-29 2021-04-27 Merck Sharp & Dohme Corp. Substituted n′-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors
US10927086B2 (en) 2017-02-24 2021-02-23 Merck Sharp & Dohme Corp. Substituted sulfoximine compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors

Also Published As

Publication number Publication date
CA3057312A1 (en) 2018-10-04
WO2018183097A1 (en) 2018-10-04
EP3600299A1 (en) 2020-02-05
JP2020515528A (ja) 2020-05-28
RU2765371C2 (ru) 2022-01-28
CN110461326A (zh) 2019-11-15
AU2018243640A1 (en) 2019-09-12
US20200102278A1 (en) 2020-04-02
EP3600299B1 (en) 2022-11-30
RU2019130589A (ru) 2021-04-29
US11034661B2 (en) 2021-06-15
EP3600299A4 (en) 2020-09-30
RU2019130589A3 (es) 2021-07-01
BR112019020080A2 (pt) 2020-04-28
KR20190133171A (ko) 2019-12-02

Similar Documents

Publication Publication Date Title
GEP20207105B (en) 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors
MX2021013075A (es) Oxisteroles y metodos de uso de los mismos.
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
EA201992601A1 (ru) Конденсированное имидазопиперидиновое соединение, являющееся ингибитором jak
MX2016017030A (es) Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos.
EA201792259A1 (ru) Бензимидазольные и имидазопиридиновые карбоксимидамидные соединения
EA201650031A1 (ru) Производные пирролидин-2,5-диона, фармацевтические композиции и способы применения в качестве ингибиторов ido1
EP4316591A3 (en) Oxysterols and methods of use thereof
MX2021014531A (es) Compuestos de aminopurina sustituida, composiciones del mismo, y metodos de tratamiento con los mismos.
MX2016016516A (es) Inhibidores de fosfatidilinositol 3-cinasa.
MY197698A (en) Oxysterols and methods of use thereof
PH12019550140A1 (en) Piperidine-substituted mnk inhibitors and methods related thereto
MX2016016530A (es) Inhibidores de fosfatidilinositol 3-quinasa.
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
PH12017502009A1 (en) Novel sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of virus infection
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
TN2017000031A1 (en) Imidazopyridazine compounds
PH12016502130B1 (en) Novel pyrrolopyrimidine compound or salt thereof, pharmaceutical composition containing same, especially agent for prevention and/or treatment of tumors etc based on nae inhibitory effect
MX2018013164A (es) Compuestos novedosos de imidazopiridina sustituida como inhibidores de indolamina-2,3-dioxigenasa y/o triptofano-2,3-dioxigenasa.
NZ746906A (en) Oxaborole esters and uses thereof
EA201792425A1 (ru) Трициклические соединения и их применение в качестве ингибиторов фосфодиэстераз
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
WO2020251871A3 (en) Novel substituted tetrahydroquinolin compounds as indoleamine 2,3-dioxygenase (ido) inhibitors